← The Wire
SLSNasdaq
SELLAS Life Sciences Group, Inc.
Pharmaceutical Preparations · DE · CIK 1390478
Develops novel cancer therapeutics, including peptide immunotherapy and CDK9 inhibitors
red 8-K · 90d
$1.54B
Market cap
$15.45
Last close
+24.7%
1D
+81.1%
5D
33.1M
Volume
Price · last 39 sessions+207.8%
May 4L $4.87 · H $15.45Jun 29
464
Total filings
Jun 25, 2026
Last filing
12/31
Fiscal year end
SC 13GSELLAS LIFE SCIENCES GROUP, INC.Feb 7, 2024SC 13GSC 13GSep 21, 2020SC 13GSCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIPAug 25, 2020SC 13GSC 13GJan 17, 2020SC 13GSC 13GJun 24, 2019SC 13GSC 13GFeb 12, 2019SC 13GACQUISITION OF BENEFICIAL OWNERSHIPJul 23, 2018SC 13GJULY 23, 2018Jul 23, 2018SC 13GSELLAS LIFE SCIENCES GROUP, INC.Jul 18, 2018SC 13GSC 13GFeb 17, 2017SC 13GSC 13GFeb 17, 2017SC 13GSABBY 13G GALE 2.15.17Feb 15, 2017SC 13GSC 13GJan 30, 2017SC 13GSC 13GJul 15, 2016SC 13GSABBY 13G GALE 6.12.16Jul 12, 2016SC 13GSC 13GJan 29, 2014SC 13GSABBY GALE 13G 01.02.13Jan 2, 2013
Insider Activity
In the 90 days to Nov 19, 2025: 1 insider bought $101K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 19, 2025 | Kalin Katherine BachDirector | Buy | 63,400 | $1.59 | $101K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance